VX-548 Significantly Reduces Moderate to Severe Acute Pain, Phase III Program Data Reveal

VX-548 demonstrated a more rapid onset to meaningful pain relief post-surgery compared with placebo.

Related Keywords

,Jessica Oswald ,Reshma Kewalramani ,University Of California San Diego ,Vertex Acute Pain Steering Committee ,Pain Intensity Difference ,Numeric Pain Rating Scale ,Patient Global Assessment ,Emergency Medicine ,Pain Medicine ,California San Diego ,